Market Place
Sourcing Support
Onconova & Trawsfynydd Announce Business Combination to Form Traws Pharma
02 Apr 2024 //
GLOBENEWSWIRE
Traws Pharma Announces New Employee Inducement Grants
02 Apr 2024 //
GLOBENEWSWIRE
Onconova Therapeutics Rigosertib Poster Selected for AACR 2024
08 Mar 2024 //
GLOBENEWSWIRE
Onconova Therapeutics Narazaciclib Highlights Activity in Mantle Cell Lymphoma
12 Dec 2023 //
GLOBENEWSWIRE
Onconova`s Narazaciclib Data Highlights Anti-Tumor Activity v. Other CDK4/6i™s
08 Dec 2023 //
GLOBENEWSWIRE
Onconova Therapeutics to Present at NobleCon19
28 Nov 2023 //
GLOBENEWSWIRE
Onconova Therapeutics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Onconova Therapeutics to Announce Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Onconova Therapeutics™ ASH Poster To Focus on Narazaciclib in MCL
02 Nov 2023 //
GLOBENEWSWIRE
Onconova Expands Leadership Team with Two Key Appointments
24 Oct 2023 //
GLOBENEWSWIRE
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
19 Oct 2023 //
GLOBENEWSWIRE
Encouraging Rigosertib Data Presented at EADV as Late Breaker
12 Oct 2023 //
GLOBENEWSWIRE
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib
28 Sep 2023 //
GLOBENEWSWIRE
Onconova to Participate at the H.C. Wainwright 25th Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
Onconova Therapeutics Announces Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Onconova to Announce Second Quarter 2023 Financial Results on August 10, 2023
03 Aug 2023 //
GLOBENEWSWIRE
Onconova Presents Data on Narazaciclib at the 17th International Conference
14 Jun 2023 //
GLOBENEWSWIRE
Onconova Announces Poster Presentation at the American Society of Annual Meeting
05 Jun 2023 //
GLOBENEWSWIRE
Onconova Announces Dosing of First Participant in Phase 2 Trial of Rigosertib
25 May 2023 //
GLOBENEWSWIRE
Onconova Therapeutics Reports 1Q 2023 FYR Results and Provides Business Update
15 May 2023 //
GLOBENEWSWIRE
Onconova to Participate in R&D Showcase on Narazaciclib in Endometrial Cancer
12 May 2023 //
GLOBENEWSWIRE
Onconova doses first patient in trial of endometrial cancer combo therapy
12 May 2023 //
CLINICAL TRIALS ARENA
Onconova Doses First Patient in Phase 1/2a Trial of Narazaciclib with Letrozole
11 May 2023 //
GLOBENEWSWIRE
Onconova to Present at the ISID International Epidermolysis Bullosa Symposium
08 May 2023 //
GLOBENEWSWIRE
Onconova to Corporate Update & Announce 1Q 2023 FYR on May 15, 2023
04 May 2023 //
GLOBENEWSWIRE
Onconova Announces the Presentation of New Preclinical Data on Narazaciclib
19 Apr 2023 //
GLOBENEWSWIRE
Onconova Announces the Unexpected Passing of CMO Dr. Mark Gelder
06 Apr 2023 //
GLOBENEWSWIRE
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration
23 Mar 2023 //
GLOBENEWSWIRE
Onconova Reports Full Year 2022 Financial Results and Provides Business Update
16 Mar 2023 //
GLOBENEWSWIRE
Onconova Announces Upcoming Poster Presentations at the AACR Annual Meeting
15 Mar 2023 //
GLOBENEWSWIRE
Onconova Therapeutics Announce Q4 and Full Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
Onconova Presents Data Characterizing Rigosertib Mechanisms of Action
07 Mar 2023 //
GLOBENEWSWIRE
Onconova Announces Clinical Data Demonstrating Rigosertib Monotherapy Activity
07 Feb 2023 //
GLOBENEWSWIRE
Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference
01 Feb 2023 //
GLOBENEWSWIRE
Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series
26 Jan 2023 //
GLOBENEWSWIRE
Onconova Appoints Drs. Peter Atadja and Trafford Clarke to Board of Directors
19 Dec 2022 //
GLOBENEWSWIRE
Onconova to Present at the Upcoming MedInvest Oncology Conference
07 Dec 2022 //
GLOBENEWSWIRE
Onconova to Present at the Upcoming RHK Capital Disruptive Growth Conference
28 Nov 2022 //
GLOBENEWSWIRE
Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib
14 Nov 2022 //
GLOBENEWSWIRE
Onconova to Provide Corporate Update and Announce Third Quarter Result
07 Nov 2022 //
GLOBENEWSWIRE
Onconova Therapeutics to Present at the Ladenburg Thalmann 2022
22 Sep 2022 //
GLOBENEWSWIRE
Onconova Announces Updated Data from Investigator-sponsored Ph 1/2a Rigosertib
12 Sep 2022 //
GLOBENEWSWIRE
Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual
01 Sep 2022 //
GLOBENEWSWIRE
Onconova Therapeutics Reports Q2 2022 Rusult and Provides Business Update
11 Aug 2022 //
GLOBENEWSWIRE
Onconova Tx Announce Second Quarter Financial Results on August 11, 2022
04 Aug 2022 //
GLOBENEWSWIRE
Onconova Therapeutics Announces Key Management Promotions
13 Jun 2022 //
GLOBENEWSWIRE
Onconova Announces Abstract at ASCO 2022 Highlighting Narazaciclib activity
26 May 2022 //
GLOBENEWSWIRE
Onconova Therapeutics Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Onconova Therapeutics Accepts Abstract for Publication at the ASCO
27 Apr 2022 //
GLOBENEWSWIRE
Onconova Therapeutics to Present at the Next Generation Kinase Inhibitors Summit
23 Mar 2022 //
GLOBENEWSWIRE
Onconova files to raise dose cap in solid tumor trial
19 Mar 2022 //
FIERCEBIOTECH
Onconova Tx Reports FY 2021 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
Onconova Tx to Announce Q4 and FY 2021 Financial Results on March 17, 2022
10 Mar 2022 //
GLOBENEWSWIRE
Onconova to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
04 Jan 2022 //
GLOBENEWSWIRE
Onconova Therapeutics Appoints Adar Makovski Silverstein as Director
13 Dec 2021 //
GLOBENEWSWIRE
Onconova Therapeutics to Present at the Piper Sandler 33rd AVHC
22 Nov 2021 //
GLOBENEWSWIRE
Onconova Reports Q3 2021 Financial Results and Provides Business Update
11 Nov 2021 //
GLOBENEWSWIRE
Onconova Therapeutics, Inc. Announces Closing of $21 M Public Offering
28 Sep 2021 //
GLOBENEWSWIRE
Onconova Therapeutics shares drop 14% on $21M capital raise
24 Sep 2021 //
SEEKINGALPHA
Onconova Announces Pricing of $21 Million Public Offering of Common Stock
24 Sep 2021 //
GLOBENEWSWIRE
